Pacira BioSciences
PCRX
180 hedge funds and large institutions have $2.29B invested in Pacira BioSciences in 2016 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 77 increasing their positions, 60 reducing their positions, and 56 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 60
16% less funds holding
Funds holding: 214 → 180 (-34)
16% less call options, than puts
Call options by funds: $22.9M | Put options by funds: $27.3M
30% less capital invested
Capital invested by funds: $3.29B → $2.29B (-$999M)
45% less funds holding in top 10
Funds holding in top 10: 11 → 6 (-5)
57% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 56
Top Buyers
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$94.2M |
| 2 |
FAM
Fred Alger Management
New York
|
+$63.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.8M |
| 4 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$15.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$15.9M |
Top Sellers
PCRX Hedge Fund Activity: Q1 2016 in Review
180 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2016, worth a combined $2.29B — down 30% from $3.29B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of PCRX and 24 opened new positions — a net loss of 32 holders — while 60 trimmed existing stakes and 77 added.
The largest buyer was Maverick Capital, opening a new position worth an estimated $94.2M. The largest seller was Janus Henderson Investors US, exiting entirely with an estimated $51.5M sold.
- 180 institutional investors held Pacira BioSciences (PCRX) as of Q1 2016, down from 214 in Q4 2015.
- Funds reported $2.29B of Pacira BioSciences stock for Q1 2016, down 30% quarter-over-quarter.
- 24 funds opened new Pacira BioSciences positions in Q1 2016 and 56 closed out, a net change of -32 holders.
- The largest Pacira BioSciences buyer in Q1 2016 was Maverick Capital, an estimated $94.2M added.
- The largest Pacira BioSciences seller in Q1 2016 was Janus Henderson Investors US, an estimated $51.5M sold.
Based on aggregated 13F filings for Q1 2016.